Answers are grounded in this paper and cite their sources.
Pilot experiment shows Lactobacillus 3L improves microbiome health disrupted by cyclophosphamide in rats, suggesting potential benefits for chemotherapy.
We deal with various strains of Lactobacillus that can maintain the intestinal microbiome of rats treated with cyclophosphamide, an anticancer agent (chemotherapy). We use MiSeq and various types of statistical tests to prove that cyclophosphamide in rats alters the intestinal microbiome, favoring the growth of various fungi that are extremely harmful to intestinal metabolism. On the contrary, when Lactobacillus 3L is administered together with cyclophosphamide, we prove that the microbiome is preserved by having a much better intestinal metabolism.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: